SUSAN CANDELARIA: Open Payments
NPI 1992396998 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,619 in 72 payments from 15 companies in 2025. Trend: 2023 $952 · 2024 $1,199 · 2025 $1,619
Food & beverage: $1,619
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $562 |
| Otsuka America Pharmaceutical, Inc. | 16 | $290 |
| Indivior Inc. | 5 | $115 |
| Neurocrine BioSciences, Inc. | 4 | $96 |
| E.R. Squibb & Sons, L.L.C. | 3 | $87 |
| Lundbeck LLC | 5 | $86 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $72 |
| Janssen Pharmaceuticals, Inc | 3 | $68 |
| Braeburn Inc. | 2 | $65 |
| Axsome Therapeutics, Inc. | 2 | $47 |
Products named: VRAYLAR, REXULTI, SUBLOCADE, INGREZZA, COBENFY, ABILIFY ASIMTUFII, CAPLYTA, SPRAVATO.
Industry payments across NV — which companies pay providers there.
